|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
25
|
|
pubmed:dateCreated |
2007-8-31
|
|
pubmed:abstractText |
This randomized, double-blind, placebo-controlled phase III study aimed to determine whether thalidomide prolongs survival of patients with extensive-disease small-cell lung cancer (SCLC).
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:BretonJean LucJL,
pubmed-author:DavidPhilippeP,
pubmed-author:GameroffSabineS,
pubmed-author:GenèveJeanJ,
pubmed-author:GervaisRadjR,
pubmed-author:JanicotHenriH,
pubmed-author:MaraninchiDominiqueD,
pubmed-author:PujolJean LouisJL,
pubmed-author:QuoixElisabethE,
pubmed-author:TanguyMarie-LaureML,
pubmed-author:WesteelVirginieV
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
25
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3945-51
|
|
pubmed:dateRevised |
2008-1-29
|
|
pubmed:meshHeading |
pubmed-meshheading:17761978-Carcinoma, Small Cell,
pubmed-meshheading:17761978-Disease-Free Survival,
pubmed-meshheading:17761978-Double-Blind Method,
pubmed-meshheading:17761978-Female,
pubmed-meshheading:17761978-Humans,
pubmed-meshheading:17761978-Lung Neoplasms,
pubmed-meshheading:17761978-Male,
pubmed-meshheading:17761978-Middle Aged,
pubmed-meshheading:17761978-Proportional Hazards Models,
pubmed-meshheading:17761978-Survival Rate,
pubmed-meshheading:17761978-Thalidomide
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01.
|
|
pubmed:affiliation |
Centre Hospitalier Universitaire, Montpellier Cedex 5, France. jl-pujol@chu-montpellier.fr
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase III
|
